Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter s Q4 Revenues Fall 5.4 Percent as Income Drops 70 Percent

NEW YORK, Feb. 17 (GenomeWeb News) - Beckman Coulter reported today that its fourth-quarter sales fell by 5.4 percent to $655.5 million from $693 million during the year-ago period.

 

Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth .

 

Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.

 

Beckman reaffirmed its outlook for 2006 that was stated on Nov. 2, 2005, when the company released its third quarter earnings report. Assuming stable currency, sales should be in the range of $2.53 billion to $2.60 billion, the company said.

 

For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.

 

Beckman CEO Scott Garrett said he expects growth in 2006 to be led by placements of the company's DxC 600 and 800 Autochemistry platforms, and of the UniCel DxI 800 immunoassay systems.

 

Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.

 

As of Dec. 31, 2005, Beckman had $57.6 million in cash and cash equivalents.

 

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.